James Ogle, who was CEO of INC Research for nine years and has been the company’s chairman since 2010, has retired.
The Raleigh-based company announced this week that David Norton, a 40-year pharmaceutical industry veteran who joined the company’s board of directors last year, is the new chairman effective immediately.
Norton’s career included a stint as CEO of Savient Pharmaceuticals in 2012. Prior to that he was chairman of global pharmaceuticals at Johnson & Johnson, a company he began working for in 1979.
Ogle joined the company in June 2003 and shortly thereafter was named CEO, a position he held until 2012. Ogle was succeeded in early 2013 by current INC CEO Jamie Macdonald.
In 2014, INC completed an initial public offering.
“Jim Ogle has been a leader at INC for decades and is a steady voice that guided the company through pivotal milestones to where it is today,” CEO Jamie Macdonald said in a statement.
INC is a contract research organization, or CRO, that help pharmaceutical and biotechnology companies design, manage and analyze clinical trials of experimental drugs. The company has nearly 1,000 employees in Raleigh.
The company’s shares closed Friday at $42.23, down 43 cents. The stock is down 9 percent this year.